Merck Ends Talks on Revolution Medicines Deal

On this episode of Stock Movers:
- CVC (CVC) shares drop after the company agreed to buy Marathon Asset Management in a cash and equity transaction with a base consideration valued at as much as $1.2 billion.
- Mankind (MNKD) shares rise after the FDA approved an update to the company’s inhaled insulin, revising recommendations for the starting mealtime dosage.
- Revolution Medicines (RVMD) shares drop on news Merck is no longer in talks to acquire biotech firm.

See omnystudio.com/listener for privacy information.